UNSPSC 51281709: Talampicillin

This classification denotes an anti-bacterial agent and ampicillin with the molecular formula C24H23N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29OJI73DPC, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester, (2s-(2alpha,5alpha,6beta(s*)))- but generally known as talampicillin, which bears US NIH Compound Identifier 39480.

UNSPSC 51281709 Talampicillin, a Commodity code, does not align with the recent state and local contract opportunities tagged to it. The four posted opportunities—ranging from naloxone and drug deactivation systems procurement to generic pharmaceuticals cooperative purchasing and therapeutic pharmacy initiatives—show minimal or no connection to talampicillin, a semisynthetic penicillin antibiotic with limited modern clinical use. State and local buyers under this code are not sourcing talampicillin itself in recent solicitations. The mismatch suggests either miscategorization of opportunities in the source system or that talampicillin occupies a narrow niche within state and local pharmaceutical procurement that is not reflected in current contract activity.

The recent opportunities indicate that state and local governments are actively procuring broader pharmaceutical and medical supply categories—generic pharmaceuticals through cooperative purchasing alliances, naloxone for community health and emergency response, and first aid supplies for fire departments—but talampicillin does not appear as a line item or focus area in any of the four posted solicitations. Seminole County's naloxone procurement (IFB60459723LAS, due July 26, 2023), the City of Tampa's medical and first aid supplies bid for the Fire Department Rescue Division (26P00145, due March 13, 2026 with an estimated $700,000 contract value), and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceuticals RFP (S1070000015802, due March 26, 2026) all target specific product categories and therapeutic needs distinct from talampicillin. The Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative RFI (HHS0017013) seeks direct-to-manufacturer prescription capabilities but does not name talampicillin among focus areas. No meaningful activity under this code supports a pursue recommendation at this time.